• Earlier in June 2026, Viatris Inc. completed a €650 million offering of 4.250% fixed-rate senior unsecured Eurobonds due June 17, 2033, priced at 99.739% of face value with attached guarantees and callable features.
• This move adds a new layer to Viatris’ capital structure just as investors are focusing on its late-stage product pipeline, free cash flow above US$2.20 billion, and value-focused analyst ratings.
• We’ll now examine how Viatris’ fresh Eurobond issuance interacts with its value-focused investment narrative and expanding late-stage pipeline.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

Viatris Investment Narrative Recap

To own Viatris today, you need to believe its late‑stage pipeline and strong free cash flow above US$2.20 billion can offset pricing pressure and reliance on mature generics. The new €650 million Eurobond does not change the near term catalyst, which is execution on more than 10 late‑stage candidates, but it does slightly increase balance sheet risk in a business that is already managing high leverage and integration complexity.

The most relevant recent announcement alongside this Eurobond is the FDA’s acceptance of Viatris’ NDA for fast‑acting meloxicam, with a PDUFA date of December 27, 2026. This acute pain candidate sits at the heart of the late‑stage pipeline story that many value‑focused analysts are watching, and its regulatory progress is a key offset to concerns about pricing, generic competition and the company’s still‑unprofitable earnings profile.

But against this constructive setup, investors should also be aware that the combination of higher debt and ongoing pricing pressure could...

Viatris' narrative projects $15.4 billion revenue and $954.5 million earnings by 2029. This requires 1.8% yearly revenue growth and a $1.251 billion earnings increase from -$296.5 million today.

Uncover how Viatris' forecasts yield a $17.50 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts paint a much harsher picture, assuming only about 1.8% annual revenue growth to roughly US$15.3 billion and earnings of US$469.0 million by 2029, so if you are worried about debt and pricing pressure, their view shows how far expectations can differ and how the new Eurobond could eventually reshape both optimistic and pessimistic narratives.

Explore 7 other fair value estimates on Viatris - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Interested In Other Possibilities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.